| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Norton, formerly known as Norton by Symantec, is a division of NortonLifeLock, and is based out of Mountain View, California.
Velosimo connects government technologies with cloud-based, easy to use, no-code integration connectors and low-code iPaaS integration development platform
Global Network Systems is a Exeter, NH-based company in the Software and Internet sector.
Canadian Molecular Research Services Inc. is a Ottawa, ON-based company in the Software & Internet sector.